A critical problem in the treatment of malignant gliomas is the extensive infiltration of individual tumor cells into adjacent brain tissues. This invasive phenotype severely limits all current therapies, and to date, no treatment is available to control the spread of this disease. Members of the tumor necrosis factor (TNF) ligand superfamily and their cognate receptors regulate various cellular responses including proliferation, migration, differentiation, and apoptosis. Specifically, the TNFRSF19/TROY gene encodes a type I cell surface receptor that is expressed on migrating or proliferating progenitor cells of the hippocampus, thalamus, and cerebral cortex. Here, we demonstrate that levels of TROY mRNA expression directly correlate with increasing glial tumor grade. Among malignant gliomas, TROY expression correlates inversely with overall patient survival.
INTRODUCTION
Glioblastoma multiforme (GBM) is the most malignant form of all primary adult brain tumors in which median patient survival remains approximately 1 year (1). A characteristic feature of GBM is the propensity of glioma cells to invade the surrounding normal brain tissue (2) (3) (4) (5) . Invasion is a dynamic process dependent upon the interplay between cell surface adhesion receptors and the cellular and extracellular matrix environments. The critical drivers of glioma invasion are not fully understood, yet a number of cell surface proteins including integrins (6, 7), L1CAM (8) , and galectin1 (9-13) have been identified as important mediators of glioma invasion. Although some advancement toward GBM treatment has been made (14) , these invasive cells still render complete surgical resection impossible and confer resistance to pro-apoptotic stimuli (2, 15) and far less to pro-autophagic stimuli (16) . Thus, improved treatment of malignant glioma awaits a means to effectively target the dispersing tumor cells and currently no anti-invasive therapies are available.
Tumor necrosis factor (TNF) and TNF receptor (TNFR) superfamilies are involved in various physiological and pathological responses, including cell survival, programmed cell death, inflammation and differentiation (17) . Previously, gene expression profiling of glioma cells (migrating in vitro and invading in vivo) revealed several candidate genes involved in glioma cell invasion, as well as survival genes with a concordant decrease in pro-apoptotic genes (18, 19) . Several candidates belonging to the TNFR superfamily emerged, including TNFRSF12A/Fn14 (18, 20) . We previously showed that TNFRSF12A/Fn14 is highly expressed in GBM specimens and is
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Copyright © 2010 American Association for Cancer Research possible factor in mediating the switch of osteoblast versus adipocyte differentiation of human multipotent mesenchymal stromal stem cells (30) .
In this study, we demonstrate that TROY mRNA is overexpressed in advanced glial tumors and is associated with poor prognosis. We provide evidence that increased TROY expression stimulates glioma cell migration and invasion via the Rac1 signaling pathway.
In addition, we demonstrate that TROY co-immunoprecipitates with the nonreceptor tyrosine kinase Pyk2 and that depletion of Pyk2 expression or Pyk2 activity suppresses TROY induced Rac1 activation and subsequent glioma cell migration. Hospital (Detroit, MI) as previously described (21) . Gene expression profiling as described previously (21) reporter was used as a control. Recombinant lentiviruses were produced as described (33) . The kinase deficient Pyk2 variant (Pyk2KD) containing the substitution of K457A was generated using the Quickchange site directed mutagenesis kit (Stratagene, La Jolla, CA). The coding sequence of Pyk2KD was excised and subcloned into the adenoviral shuttle vector pShuttle-CMV to prepare recombinant adenoviruses using the Ad-Easy system as described (34) .
Small-interfering RNA preparation and transfection. Small interfering RNA (siRNA) oligonucleotides specific for human Rac1 and non-mammalian GL2 Luciferase were previously described (35) . Validated siRNA sequences for human TROY (TROY-1, Hs_TNFRSF19_1; TROY-2, Hs_TNFRSF19_5) were purchased from Qiagen (Valencia, CA). Transient transfection of siRNA was carried out as previously described (35) . All siRNA oligonucleotides were transfected at 25 nmol/L, and no cell toxicity was Small hairpin RNA (shRNA) specifically targeting human Pyk2 (36) was assembled in the lentiviral plasmid vector pLVTHM (Addgene, Cambridge, MA) and recombinant lentiviruses were produced as previously described (37) .
Quantitative reverse transcription PCR. Total RNA from frozen tissues was extracted using Qiagen RNeasy Kit (Qiagen, Valencia, CA.), following the manufacturer's protocol. The quantity and quality of RNA were assessed with a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). cDNA was synthesized from 200 ng of total RNA as previously described (38) . Immunoblotting and protein determination were performed as described previously (22) .
For immunoprecipitation, equivalent amounts of cell lysates (500 µg) were precleared, immunoprecipitated with the appropriate antibody, and the precipitates washed twice with lysis buffer. Samples were then resuspended in 2× SDS sample buffer and boiled in the presence of 2-mercaptoethanol (Sigma), separated by SDS-PAGE, transferred to nitrocellulose overnight at 4 °C, and proteins were detected as described previously (22) . Cellular migration was quantified in a radial cell migration assay as previously described (21) . For certain experiments, cells were transfected with siRNA targeting luciferase, TROY or Rac1. After 24 hours, cells were plated onto 10-well glass slides precoated with 10 μg/ml of human laminin as previously described (21) . Cell migration was determined over 24 hours.
Organotypic brain slice invasion assay
An ex vivo invasion assay into rat brain slices was performed as described previously 
MALDI-TOF MS
For MALDI-TOF MS, protein bands were stained with SYPRO Ruby protein staining kit Statistical analysis. Statistical analyses were performed using the two-sample t-test. P < 0.05 was considered significant. Tumor Center, Henry Ford Hospital (Detroit, MI) as previously described (21) . Gene expression profiling performed as described previously (21) was conducted on all samples using Affymetrix U133 Plus 2 GeneChips according to the manufacturer's protocol at the Neuro-Oncology Branch at the National Cancer Institute (Bethesda, MD).
For our analysis, gene expression data were normalized both per chip and per gene across all samples in the collection as described in detail in the Methods. Gene expression differences were deemed statistically significant using parametric tests where variances were not assumed equal (Welch analysis of variance specimens, TROY expression is relatively low, but is increased with increasing tumor grade and is significantly higher in GBM samples (n=82) (Fig. 1A) . To verify the results from the expression profiling, we performed QRT-PCR on independent non-neoplastic (n=10), LGA (n=6), anaplastic astrocytoma (n=4), and GBM (n=22) specimens. Normal brain specimens show relatively low mRNA levels for TROY as compared to the brain tumor samples (p < 0.01). In GBM specimens, the mRNA level of TROY is significantly higher than in NB tissue (p < 0.01) (Fig. 1B) . Next, principal component (PC) analysis was done to discern possible relationships between subgroups of samples as previously described (21), and Kaplan-Meier survival curves were developed for each PC cluster. Fig. 2A) .
To determine the role of TROY in glioma cell migration, we used RNAi to knockdown the expression of TROY in the four glioma cell lines and examined the migratory behavior of the cells on human laminin using a two-dimensional radial cell migration assay (21) . siRNA-mediated knockdown of TROY expression in the glioma cell lines with two independent siRNA oligonucleotides was ~80-90% effective and has no effect on the expression of another TNRFSF member, Fn14. Representative results are
shown for U118 cells (Fig. 2B) . Knockdown of TROY expression resulted in a significant inhibition of cell migration in all four cell lines relative to control cells expressing siRNA targeting luciferase (p < 0.05, Fig. 2C ).
Overexpression of TROY in glioma cells stimulates cell migration and invasion
and TROY expression localizes to the leading edge of cell migration. To further examine the function of TROY signaling in glioma cell migration, we overexpressed HA epitope-tagged TROY in T98G glioma cell lines by lentiviral transduction (Fig. 3A) .
Overexpression of HA tagged-TROY in T98G glioma cells resulted in a two-fold increase in cell migration rate (Fig. 3B) . TROY is an orphan member of the TNFRSF, and unlike the classical TNFRSF members, TROY lacks a death domain (23) . During embryonic development, TROY is widely expressed, but its expression in the postnatal organism is restricted (23) (24) (25) (26) 28) .
The strict control of TROY expression indicates that aberrant expression may be unfavorable. Indeed, it has been recently reported that TROY is highly expressed in primary and metastatic melanoma cells, but not in melanocytes found in normal skin biopsies (39) . Similarly, we report that the levels of expression of TROY in glial tumors correlate with tumor grade with advanced GBM showing the highest expression of TROY. Similar to our previous finding with Fn14 (21) , TROY expression appears to be an indicator of poor outcome. Principle component analysis indicated that GBM patients in the short-term survival group expressed TROY at significantly increased levels as compared with GBM patients with long-term survival. Thus, the aberrant re-expression 
TNFRSF19
.1, suggests that these two TROY variants may signal differently, although that remains to be determined. We identified that the TROY variant TNFRSF19.2 was highly over-expressed in glioblastoma specimens, whereas no changes were observed in the mRNA expression of TNFRSF19.1. Elevated NF-κB activity has been observed in GBM (40, 41) and has been implicated in contributing to cellular resistance to cytotoxic intervention and promotion of expression of genes involved in cell survival and invasion (42) . As TROY mediated activation of NF-κB has been reported in experimental systems (43, 44) , it is possible that TROY overexpression in GBM may contribute to NF-κB hyperactivation and subsequently cell invasion. Rac1 has been shown to play a role in various malignant carcinoma cells and in gliomas (52, 53) . In glioma, inhibition of Rac1 expression by RNAi strongly inhibits cell migration and invasion (35, 54) . Recently, studies have shown that that certain members of the TNFRSF can regulate the activation of Rac1 (21, 55, 56) . Notably, activation of Fn14 results in the activation of Rac1 to drive glioma invasion and migration (21) . Since the activation of Rac1 occurs through the exchange of bound GDP for GTP catalyzed by one of multiple Rac guanine exchange factors (GEFs), it is likely TROY may modulate cytoskeleton dynamics by influencing one or more of the Rac GEF proteins involved in Rac1 activation, possibly through Pyk2. Importantly, several Rac GEFs, including Ect2, VAV3, TRIO, and Dock180, have been shown to be overexpressed in GBM specimens, and depletion of the expression of these GEFs by RNAi reduced Rac1 activation and inhibited glioma cell migration and invasion (38, 57) .
Interestingly, Pyk2 has been shown to modulate the activity of several Rac GEFs including VAV1 and VAV2 (58, 59) . A model of TROY signaling to mediate cell migration is shown in Fig. 6 .
In summary, we have identified an important role for the TNFRSF member TROY in glioma cell migration and invasion. Increased expression of TROY stimulates in vitro glioma cell migration and invasion, is associated with increased activation of Rac1, and correlates with poor patient outcome. Furthermore, the results indicate that TROY- functions to induce Rac1 activation potentially by influencing a Rac guanine nucleotide exchange factor (GEF) to drive glioma cell migration and invasion.
